ClinicalTrials.gg
RecruitingNCT07645287Updated Nov 10, 2026

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

A Phase 2 interventional study of GS-3242 Tablet and GS-3242 Injection in HIV-1-infection, sponsored by Gilead Sciences. Recruiting at 59 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 10, 2026Site recruiting status changed5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS-3242 plus Lenacapavir (LEN) versus continuing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)), in virologically suppressed people with HIV-1 (PWH) in treatment Group 1, 2 and 3 at Week 35. In Part B the goal of the study is to compare the effectiveness of switching to the study drugs, GS-3242 and LEN versus continuing B/F/TAF in Groups 4 and 3 at Week 26.

The primary objective of part A is to evaluate the efficacy of switching to intramuscular (IM) GS-3242 plus IM LEN versus continuing on B/F/TAF PWH who are virologically suppressed in treatment Groups 1, 2, and 3 at Week 35 and Part B is to evaluate the efficacy of switching to IM GS-3242 plus IM LEN versus continuing on B/F/TAF in PWH who are virologically suppressed in Treatment Groups 4 and 3 at Week 26.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented type 1 (HIV-1) ribonucleic acid (RNA) \< 50 copies/mL for ≥ 6 months before screening.
  • Plasma HIV-1 RNA levels \< 50 copies/mL at screening.
  • Receiving bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®) (B/F/TAF) for ≥ 6 months prior to screening.
  • No documented resistance to GS-3242 (integrase mutation Q148H/K/R plus at least 2 of the following integrase mutations: L74I/M, T97A, E138A/K/T, or G140A/C/S).

Key Exclusion Criteria:

  • Prior use of, or exposure to GS-3242 or LEN.
  • History of virologic failure while on an integrase strand transfer inhibitor (INSTI)-based regimen.
  • Prior use of any long-acting parenteral antiretroviral therapy (ART) medications such as monoclonal antibodies or broadly neutralizing antibodies targeting HIV-1, injectable cabotegravir (including oral cabotegravir lead-in), or injectable rilpivirine.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (estimated)

Study arms

  • Experimental
    Part A: Group 1 of GS-3242 + LEN

    Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by intramuscular (IM) injections of GS-3242 and LEN up to 52 weeks.

    Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

  • Experimental
    Part A: Group 2 of GS-3242 + LEN

    Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by a IM injections of GS-3242 (at a different dose than Group 1) and LEN up to 52 weeks.

    Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

  • Experimental
    Part A: Group 3 of B/F/TAF

    Participants will be randomized to continue to receive 50/200/25 mg of B/F/TAF daily for up to 52 weeks.

    Drug: B/F/TAF

  • Experimental
    Part B: Group 4 (Conditional) of GS-3242 + LEN

    Participants will be enrolled (non-randomized) to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed IM injection of GS-3242 and LEN (at different doses than Groups 1 and 2) up to 52 weeks.

    Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm

    Time frame: Week 35

  2. Part B: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot Algorithm

    Time frame: Week 26

Secondary outcomes

  1. Part A and Part B: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm

    Time frame: Week 52

  2. Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the US FDA Snapshot Algorithm

    Time frame: Week 35

  3. Part A and Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm

    Time frame: Week 52

  4. Part A: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 35

    Time frame: Baseline, Week 35

  5. Part A and Part B: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 52

    Time frame: Baseline, Week 52

  6. Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot Algorithm

    Time frame: Week 26

  7. Part B: Change From Baseline in CD4 Cell Count at Week 26

    Time frame: Baseline, Week 26

  8. Part A: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 35

    Time frame: Up to Week 35

  9. Part A and Part B: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 52

    Time frame: Up to Week 52

  10. Part B: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 26

    Time frame: Up to Week 26

  11. Part A: Group 1 and 2:Trough Concentrations of GS-3242 and LEN at Week 18

    Time frame: Week 18

  12. Part A: Group 1 and 2:Trough Concentrations of GS-3242 and LEN at Week 35

    Time frame: Week 35

  13. Part A: Group 1 and 2 and Part B: Groups 1 and 2:Trough Concentrations of GS-3242 and LEN at Week 52

    Time frame: Week 52

  14. Part B: Trough Concentrations at GS-3242 and LEN at Week 26

    Time frame: Week 26

07

Study locations

51 of 59 sites recruiting
  • Pueblo Family Physicians
    Phoenix, Arizona 85015, United States
    Not yet recruiting
  • Pacific Oak Medical Group
    Beverly Hills, California 90211, United States
    Recruiting
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
    Recruiting
  • Optimus Medical Group
    San Francisco, California 94102, United States
    Recruiting
  • University of California San Francisco, Community and Clinical Research Center
    San Francisco, California 94110, United States
    Recruiting
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
    Recruiting
  • Mills Clinical Research
    West Hollywood, California 90046, United States
    Not yet recruiting
  • University of Colorado Clinical and Translational Research Center
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • Vivent Health
    Denver, Colorado 80246, United States
    Recruiting
  • Midland Florida Clinical Research Center, LLC
    DeLand, Florida 32720, United States
    Recruiting
  • CAN Community Health Fort Lauderdale
    Fort Lauderdale, Florida 33316, United States
    Recruiting
  • Midway Immunology and Research Center
    Ft. Pierce, Florida 34982, United States
    Recruiting
  • AIDS Healthcare Foundation -Coconut Grove
    Miami, Florida 33133, United States
    Recruiting
  • Floridian Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Orlando Immunology Center, PA
    Orlanda, Florida 32803, United States
    Recruiting
  • AHF - Pensacola
    Pensacola, Florida 32504, United States
    Recruiting
  • CAN Community Health Inc.
    Sarasota, Florida 34237, United States
    Recruiting
  • Triple O Research Institute, PA
    West Palm Beach, Florida 33407, United States
    Recruiting
  • Emory University Hospital Midtown Infectious Disease Clinic
    Atlanta, Georgia 30308, United States
    Recruiting
  • Metro Infectious Disease Consultants, P.L.L.C.
    Decatur, Georgia 30033, United States
    Recruiting
  • Mercer University, Department of Internal Medicine
    Macon, Georgia 31201, United States
    Recruiting
  • Chatham County Health Department
    Savannah, Georgia 31401, United States
    Recruiting
  • Be Well Medical Center
    Berkeley, Michigan 48072, United States
    Recruiting
  • KC CARE Health Center
    Kansas City, Missouri 64111, United States
    Recruiting
  • Southampton Community Healthcare
    St Louis, Missouri 63139, United States
    Recruiting
  • ID care
    Hillsborough, New Jersey 08844, United States
    Recruiting
  • Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
    Recruiting
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
    Recruiting
  • AXCES Research Group, LLC
    Sante Fe, New Mexico 87505, United States
    Recruiting
  • Brooklyn Clinical Research
    Brooklyn, New York 11226, United States
    Recruiting
  • NewYork-Presbyterian Queens
    Flushing, New York 11355, United States
    Recruiting
  • NYU Langone Health Vaccine Center
    New York, New York 10016, United States
    Recruiting
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
    Not yet recruiting
  • The Brody School of Medicine at East Carolina University
    Greenville, North Carolina 27858, United States
    Not yet recruiting
  • Rosedale Health and Wellness
    Huntersville, North Carolina 28078, United States
    Recruiting
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
    Not yet recruiting
  • Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
    Recruiting
  • St. Hope Foundation
    Bellaire, Texas 77401, United States
    Recruiting
  • Prism Health North Texas
    Dallas, Texas 75208, United States
    Recruiting
  • North Texas Infectious Disease Consultants, P.A.
    Dallas, Texas 75246, United States
    Recruiting
  • AXCES Research Group, LLC
    El Paso, Texas 79902, United States
    Recruiting
  • Texas Centers for Infectious Disease Associates
    Fort Worth, Texas 76109, United States
    Not yet recruiting
  • The Crofoot Research Center, INC.
    Houston, Texas 77098, United States
    Recruiting
  • Diagnostic Clinic of Longview
    Longview, Texas 75605, United States
    Recruiting
  • AXCES Research Group, LLC
    Salt Lake City, Utah 84102, United States
    Recruiting
  • Clinical Alliance for Research& Education - Infectious Diseases, LLC(CARE-ID
    Annandale, Virginia 22003, United States
    Recruiting
  • TribalMed PLLC
    Seattle, Washington 98104, United States
    Recruiting
  • MultiCare-Deaconess Medical Office Building 2
    Spokane, Washington 99202, United States
    Not yet recruiting
  • Taylor Square Private Clinic
    Surry Hills, New South Wales 2010, Australia
    Recruiting
  • Momentum Clinical Research Darlinghurst
    Sydney, New South Wales 2010 NSW, Australia
    Recruiting
  • East Sydney Doctors
    Sydney, New South Wales 2010, Australia
    Recruiting
  • Prahran Market Clinic,
    South Yarra, Victoria 3141, Australia
    Recruiting
  • CMU du Quartier Latin
    Montreal, H2L 5B1, Canada
    Recruiting
  • McGill University Health Centre
    Montreal, H4A 3J1, Canada
    Recruiting
  • Spectrum Health
    Vancouver, V6Z2T1, Canada
    Recruiting
  • Proyecto ACTU
    Rio Piedras, PR 00925, Puerto Rico
    Recruiting
  • Clinical Research Puerto Rico
    San Juan, PR 00909, Puerto Rico
    Recruiting
  • HOPE Clinical Research
    San Juan, PR 00909, Puerto Rico
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartActual
Jun 15, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Apr 2033
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed. 8 sites changed recruiting status (6 now not yet recruiting, 2 now recruiting)
Show 8 sites
  • Ruane Clinical Research Group Inc. · Los Angeles, United StatesActive, not recruiting→Recruiting
  • Spectrum Health · Vancouver, CanadaActive, not recruiting→Recruiting
  • Pueblo Family Physicians · Phoenix, United StatesActive, not recruiting→Not yet recruiting
  • Mills Clinical Research · West Hollywood, United StatesActive, not recruiting→Not yet recruiting
  • University of Colorado Clinical and Translational Research Center · Aurora, United StatesActive, not recruiting→Not yet recruiting
  • Montefiore Medical Center · The Bronx, United StatesActive, not recruiting→Not yet recruiting
  • Texas Centers for Infectious Disease Associates · Fort Worth, United StatesActive, not recruiting→Not yet recruiting
  • MultiCare-Deaconess Medical Office Building 2 · Spokane, United StatesActive, not recruiting→Not yet recruiting
Show 5 added (4 United States, 1 Canada)
  • Mills Clinical Research · West Hollywood, United States
  • University of Colorado Clinical and Translational Research Center · Aurora, United States
  • McGill University Health Centre · Montreal, Canada
  • The Brody School of Medicine at East Carolina University · Greenville, United States
  • University of Cincinnati · Cincinnati, United States
Show 1 removed
  • McGill University Health Centre · Montreal, Canada
across 2 updates, Oct 15, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    2 sites added. 6 sites changed recruiting status (6 now not yet recruiting)
    Show 6 sites
    • Pueblo Family Physicians · Phoenix, United StatesActive, not recruiting→Not yet recruiting
    • Mills Clinical Research · West Hollywood, United StatesActive, not recruiting→Not yet recruiting
    • University of Colorado Clinical and Translational Research Center · Aurora, United StatesActive, not recruiting→Not yet recruiting
    • Montefiore Medical Center · The Bronx, United StatesActive, not recruiting→Not yet recruiting
    • Texas Centers for Infectious Disease Associates · Fort Worth, United StatesActive, not recruiting→Not yet recruiting
    • MultiCare-Deaconess Medical Office Building 2 · Spokane, United StatesActive, not recruiting→Not yet recruiting
    Show 2 added (2 United States)
    • The Brody School of Medicine at East Carolina University · Greenville, United States
    • University of Cincinnati · Cincinnati, United States
    + 1 other change: verification date
  2. Oct 15, 2026
    3 sites added, 1 site removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Ruane Clinical Research Group Inc. · Los Angeles, United StatesActive, not recruiting→Recruiting
    • Spectrum Health · Vancouver, CanadaActive, not recruiting→Recruiting
    Show 3 added (2 United States, 1 Canada)
    • Mills Clinical Research · West Hollywood, United States
    • University of Colorado Clinical and Translational Research Center · Aurora, United States
    • McGill University Health Centre · Montreal, Canada
    Show 1 removed
    • McGill University Health Centre · Montreal, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07645287
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jun 15, 2026
Primary completion
Aug 2027 (estimated)
Completion
Apr 2033 (estimated)
Last update
Nov 10, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GS-3242 · Lenacapavir · Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion